NASDAQ:SGMO Stock Quote
0.8573
+0.00 (0.00%)
Sangamo Therapeutics is a biotechnology company focused on developing groundbreaking gene-editing therapies and genomic medicine to address a range of genetic diseases and disorders
By leveraging its expertise in gene modulation and genome editing technologies, including zinc finger proteins, the company aims to create innovative treatments that can permanently alter or correct genetic mutations at the DNA level. Sangamo is committed to advancing its pipeline of therapeutic candidates through rigorous research and clinical trials, collaborating with a variety of partners to expedite the development of transformative therapies for patients in need.
Via Benzinga · March 18, 2025
U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading.
Via Benzinga · March 18, 2025
Via Benzinga · March 18, 2025
Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.
Via Stocktwits · March 18, 2025

Via Benzinga · January 27, 2025

Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.
Via Benzinga · February 21, 2025

Stocks are lower midday, as Wall Street heads for its second consecutive winning year.
Via Talk Markets · December 31, 2024

Via Benzinga · December 31, 2024

Via Benzinga · December 31, 2024

Via Benzinga · December 31, 2024

Via Benzinga · December 31, 2024

Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results.
Via Benzinga · December 31, 2024

Via Benzinga · December 31, 2024

Via Benzinga · December 31, 2024

Via Benzinga · December 31, 2024

U.S. stock futures were trading higher on Tuesday following Monday's selloff. All four index futures rose in trade.
Via Benzinga · December 31, 2024

U.S. stock futures down, investors eye EHang, Sangamo, Cemtrex, CompoSecure, Ambow. Check out Benzinga's premarket coverage & top tech stocks to watch.
Via Benzinga · December 31, 2024

U.S. stock futures climbed on Thursday in premarket hours after a hawkish cut from the Federal Reserve on Wednesday.
Via Benzinga · December 19, 2024

Via Benzinga · December 19, 2024

Via Benzinga · December 16, 2024